Antigen-specific alloimmune T-cell response

Antigen-specific alloimmune T-cell responses are the primary immunological drivers of graft rejection in liver transplantation. This complex biological process involves the recognition of donor-derived alloantigens, primarily Human Leukocyte Antigens (HLA), by recipient T-cell receptors (TCR) through direct, indirect, or semi-direct pathways (Wood et al., 2013, Cold Spring Harb Perspect Med). Upon activation, these alloreactive T-cells undergo clonal expansion and differentiate into effector cells that mediate graft injury via cytokine production and direct cytotoxicity (Levitsky & Feng, 2018, Hepatology). Therapeutic management relies on immunosuppressive drugs such as Tacrolimus and Ciclosporin, which inhibit calcineurin to prevent T-cell activation, or Mycophenolate mofetil, which inhibits lymphocyte proliferation (Starzl et al., 1989, Lancet). Monitoring these responses through biomarkers like IFN-gamma ELISPOT or donor-specific antibodies is essential for managing rejection risk and pursuing operational tolerance (Ashokkumar et al., 2009, Hum Immunol). However, chronic suppression of these responses carries significant safety risks, including increased susceptibility to opportunistic infections and the development of malignancies like post-transplant lymphoproliferative disorder (Dummer et al., 1983, N Engl J Med).

Other names

Alloreactive T-cell responseAlloantigen-specific T-cell activationT-cell mediated rejectionTCMRHost-versus-graft response

Inhibition of T-cell activation and proliferation through calcineurin inhibition, mTOR inhibition, IL-2 receptor antagonism, or costimulation blockade.